Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 47,200 shares, a growth of 38.4% from the September 15th total of 34,100 shares. Based on an average daily trading volume, of 41,000 shares, the short-interest ratio is presently 1.2 days.
Institutional Investors Weigh In On Entera Bio
An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC acquired a new stake in Entera Bio Ltd. (NASDAQ:ENTX – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 22,040 shares of the company’s stock, valued at approximately $37,000. 14.11% of the stock is owned by institutional investors.
Entera Bio Stock Down 3.8 %
Shares of Entera Bio stock opened at $1.79 on Tuesday. Entera Bio has a 52-week low of $0.52 and a 52-week high of $3.35. The firm’s 50 day moving average price is $1.80 and its 200-day moving average price is $1.97. The company has a market cap of $64.06 million, a P/E ratio of -6.39 and a beta of 1.57.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a research note on Monday, October 7th.
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Further Reading
- Five stocks we like better than Entera Bio
- What Are Growth Stocks and Investing in Them
- Don’t Sleep on Nokia: Quietly Accelerating Into Infinera Merger
- Business Services Stocks Investing
- Tesla Stock: Finding the Bottom or Moving On?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Stanley Druckenmiller’s Latest Moves: What They Mean for You
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.